SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Izzy who wrote (5250)9/2/1998 11:42:00 PM
From: George T. Santamaria  Read Replies (2) | Respond to of 6136
 
Guess I have to say that the proposal sounds a little flaky!

Seems like they will be diluting the hell out of the current float and leaving a lot of the shares out for an undesignated purpose. Maybe that will help mgt. to further enrich themselves while diluting our equity. They are fat enough, in my opinion.

It's hard to believe that that with a common infrastructure, shared mgt. and a lot of shared resources, that the performance tracking will be very accurate. Just by the allocation of expenses such as the maintenance of what will be common facilities, they have broad latitude to cook the books.

I think that management, in spite of their successes, still has a lot of accountability to their basic mission, which used to be building an R&D pipeline which cranks out two products a year. Let's hope that they are not losing their way.

Agouron still has to deliver on AG3340 in a timely manner and the divisional proposal won't change a thing. Vote Nay!




To: Izzy who wrote (5250)9/3/1998 2:00:00 PM
From: Steve Fancy  Read Replies (1) | Respond to of 6136
 
I anxiously looked for AGPH in this story but not to be found...

Execs From 12 Biotech Firms, Analysts Meg Malloy and Eric Schmidt Highlight Informed Investors Boston Biotech Stocks Forum Sept. 15

BusinessWire, Thursday, September 03, 1998 at 13:36

BOSTON--(BW HealthWire)--Sept. 3, 1998--Biotechnology, an
industry poised to drive medical miracles in the next millennium, is
in the spotlight at the First Informed Investors Boston Biotechnology
Stocks Forum Tuesday Sept. 15 at the Back Bay Hilton. The Forum runs
from 8:30 a.m.-4 p.m. The public is welcome.
Also, presentations by executives from 12 publicly-traded biotech
companies, prominent industry analysts Meg Malloy of Hambrecht & Quist
and Eric Schmidt, Ph.D of Cowen & Co. will offer current insight and
perspective on this rapidly-growing and fast-changing industry.
"This is an opportunity for individual investors to gain access
to executives from leading biotechnology companies poised to
revolutionize medical care in the next century," said Steve Chanecka,
President of Sacramento-based Informed Investors. "Not only is the
Forum highly educational, but it gives investors an upfront, personal
look at companies that may become stock market winners in coming
years."
Executives scheduled to give attendees full analyst-style
presentations are: David Hilson, President/CEO, and Dr. Marc Lanser,
Chief Science Officer, Boston Life Sciences (NASDAQ:BLSI); Stuart
Essig, President/CEO, Integra LifeSciences (NASDAQ:IARTD); James
Chamberlain, President/CEO, BioSource International (NASDAQ:BIOI);
Joseph Costello, Chairman/CEO, XOMA Corp. (NASDAQ:XOMA), Tim Surgenor,
President, Genzyme Tissue Repair (NASDAQ:GENZL); Richard Love,
President/CEO, Ilex Oncology (NASDAQ:ILXO); Paul Maier, CFO, Ligand
Pharmaceuticals (NASDAQ:LGND); Dr. Una Ryan, CEO, T Cell Sciences
(NASDAQ:TCEL); Elizabeth Woo, Director of Investor Relations, Biogen
(NASDAQ:BGEN); and Steven Basta, VP/Corp. Development, Creative
BioMolecules (NASDAQ:CBMI). To be announced are executives from
Repligen (NASDAQ:RGEN) and Genzyme Transgenics (NASDAQ:GZTC).
Executives will give 20-25 minute presentations, followed by
question-and-answer period.
The cost to attend is $40 prepaid, $55 at the door (student
rate,$20). Call Informed Investors at 800/992-4683 to register. Audio
tapes will be available for investors unable to attend. The full set
(seven cassettes) are $50 plus $4.95 S/H which includes all company
presentations plus keynote speakers. Individual tapes are $18.
Transcripts of the Malloy's and Schmidt's comments are $25. Access
Informed Investors' website at informedinvestors.com for
more information and updates.
Informed Investors has been holding Forums since 1993 and has
developed into a leading conduit of current financial information from
small and mid-cap growth companies to the retail investor community
(i.e. individual investors). Forums are held throughout the nation and
focus on numerous sectors including biotechnology, technology, growth,
electronics, REITs, software, energy and others. In 1998, Forums have
been held throughout California in Emeryville, Sacramento, San Jose,
San Diego, San Francisco, Santa Clara and Milpitas. Also, Forums have
been held in Boca Raton, Clearwater and Orlando, FL, Seattle, Dallas,
Atlanta, Bethesda, MD, and Englewood, NJ.
"We are pleased with the development of our Forums," commented
Tim Quast, Chief Operating Officer of Informed Investors. "While in
the past we've had large companies participate, such as Intel
(NASDAQ:INTC), Lucent (NYSE:LU), Advanced Micro Devices NYSE:AMD) and
others, we find individual investors are interested in established
companies that may not be well known or covered extensively by Wall
Street analysts. Those are the companies that hold the most
opportunity to find the next Microsoft (NASDAQ:MSFT), Cisco
(NASDAQ:CSCO), Yahoo (NASDAQ:YHOO) or America Online (NYSE:AOL).
"Also, we have a growing base of investors who cannot attend the
Forums but get the next best thing from the audio tapes, video tapes
and transcripts we make available immediately after the Forum," Quast
added. "This works well for companies, too, because we facilitate the
communication of information from them cost effectively. It's a format
that works for both investors and companies. We intend to dramatically
expand our reach in 1999 with more companies in more cities."
On Saturday Sept. 12, Informed Investors is hosting its first
NY/NJ BioPharma Forum in Englewood, N.J. Jim McCamant, Editor of the
Medical Technology Stock Letter (www.bioinvest.com) is the keynote
speaker. Executives presenting are from Genentech (NYSE:GNE),
Immunomedics (NASDAQ:IMMU), Alteon (NASDAQ:ALTN), Organogenesis
(AMEX:ORG), Inhale Therapeutics (NASDAQ:INHL), SunPharm (NASDAQ:SUNP)
and AVI BioPharma (NASDAQ:AVII). Call 800/992-4683 for more
information. Audio tapes are available.

CONTACT: Informed Investors, Inc.
Steve Chanecka, Sean Finnigan, 916/448-8222
or 800/992-4683

KEYWORD: MASSACHUSETTS NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICINE BANKING TRADESHOW

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com

Copyright 1998, Business Wire